NCT03980821: A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies

NCT03980821
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 20 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with a history of seizures or CNS metastasis
https://ClinicalTrials.gov/show/NCT03980821

Comments are closed.

Up ↑